Akash Malik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Akash Malik has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Davendra K. Taneja
Department of Community Medicine, Maulana Azad Medical College, New Delhi, India
3 shared publications- Davendra Kumar Taneja
Department of Community Medicine, Maulana Azad Medical College, New Delhi, India
2 shared publications K. Rajeshwari
Maulana Azad Medical College
2 shared publications- Anita Shet
International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA
1 shared publication - Arindam Ray
Gates Foundation, New Delhi 110067, India
1 shared publication - Bhrigu Kapuria
UNICEF, India
1 shared publication
Latest Publications
- 9 May 2015
- Published by Oxford University Press (OUP) in International Journal for Quality in Health Care
- Vol. 27 (3) , 201-206
An assessment of facilities and services at Anganwadi centers under the Integrated Child Development Service scheme in Northeast District of Delhi, India
Objective The current study was aimed to assess the facilities and services being provided at the Anganwadi Centres (AWCs) by the Anganwadi workers with regards to the norms laid down by Integrated Child development Service (ICDS) scheme, with special emphasis on the children of 0–6 years of age. Design Cross-sectional study. Setting A resettlement colony of North-West District of Delhi, having a population of hundred thousand. Participants A total of 41 AWCs were present in the study area and were included in our study. The Anganwadi workers at these AWCs were interviewed. Main Outcome Measures The outcome measures were the facilities present at the AWCs and knowledge of Anganwadi workers regarding the services to be provided and revised supplementary nutrition norms laid down by ICDS. Results The AWCs in the area were covered under three projects namely Project A, B and C consisting of 18, 9 and 14 AWCs, respectively. The mean room size for all the AWCs was 108.97 ± 62.18 square feet. A weighing machine was present in 29 (70.7%) of the AWCs. Growth charts for growth monitoring of children were present in 28 (68.3%) of AWCs. A drug kit was not present in 14 (34.1%) of the 41 AWCs. The mean number of children of 0–3 years enrolled per AWC was 45.78 ± 14.07. However, the mean number of children present at the time of the visit at the AWCs was 6.24 ± 5.39. Knowledge of Anganwadi workers regarding revised norms for calorie and protein for beneficiaries was found to be poor. Conclusion This study showed a lack of facilities at the AWCs and poor knowledge of Anganwadi workers. Thus a regular training and supportive supervision of the Anganwadi workers is recommended along with the availability of adequate facilities and infrastructures.
- 9 May 2015
- Published by Oxford University Press (OUP) in International Journal for Quality in Health Care
- Vol. 27 (3) , 201-206
An assessment of facilities and services at Anganwadi centers under the Integrated Child Development Service scheme in Northeast District of Delhi, India
Objective The current study was aimed to assess the facilities and services being provided at the Anganwadi Centres (AWCs) by the Anganwadi workers with regards to the norms laid down by Integrated Child development Service (ICDS) scheme, with special emphasis on the children of 0–6 years of age. Design Cross-sectional study. Setting A resettlement colony of North-West District of Delhi, having a population of hundred thousand. Participants A total of 41 AWCs were present in the study area and were included in our study. The Anganwadi workers at these AWCs were interviewed. Main Outcome Measures The outcome measures were the facilities present at the AWCs and knowledge of Anganwadi workers regarding the services to be provided and revised supplementary nutrition norms laid down by ICDS. Results The AWCs in the area were covered under three projects namely Project A, B and C consisting of 18, 9 and 14 AWCs, respectively. The mean room size for all the AWCs was 108.97 ± 62.18 square feet. A weighing machine was present in 29 (70.7%) of the AWCs. Growth charts for growth monitoring of children were present in 28 (68.3%) of AWCs. A drug kit was not present in 14 (34.1%) of the 41 AWCs. The mean number of children of 0–3 years enrolled per AWC was 45.78 ± 14.07. However, the mean number of children present at the time of the visit at the AWCs was 6.24 ± 5.39. Knowledge of Anganwadi workers regarding revised norms for calorie and protein for beneficiaries was found to be poor. Conclusion This study showed a lack of facilities at the AWCs and poor knowledge of Anganwadi workers. Thus a regular training and supportive supervision of the Anganwadi workers is recommended along with the availability of adequate facilities and infrastructures.
- 1 October 2014
- Published by Springer Nature in Indian Pediatrics
- Vol. 51 (10) , 780-784
Zinc supplementation for prevention of acute respiratory infections in infants: A randomized controlled trial
To study the effect of 2 weeks of prophylactic zinc supplementation on incidence and duration of acute respiratory infections.
- 1 October 2014
- Published by Springer Nature in Indian Pediatrics
- Vol. 51 (10) , 780-784
Zinc supplementation for prevention of acute respiratory infections in infants: A randomized controlled trial
To study the effect of 2 weeks of prophylactic zinc supplementation on incidence and duration of acute respiratory infections.
- 7 February 2014
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 81 (12) , 1353-1357
Pentavalent Vaccine and Adverse Events Following Immunization—Untangling the Misinterpretations
In April 2008, the National Technical Group on Immunization (NTAGI) Sub-committee on H. influenza type b (Hib) vaccine recommended that Hib containing pentavalent vaccine should be introduced in the country. Subsequently liquid pentavalent vaccine (LPV) was launched in the Kerala and Tamil Nadu on a pilot basis in December 2011. The introduction of LPV in these two states was followed by reported deaths in infants who had received LPV. An exhaustive summary of media reports and previous literature has since been made available at various fora which have been supplemented with estimations of the damage the LPV may cause. It has thus been concluded that the LPV is bound to cause more number of infant deaths than it will save from Hib meningitis and pneumonia. The current paper aims to clear some of the misinterpretations and miscalculations so that lives of 72,000 infants can be saved.
- 7 February 2014
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 81 (12) , 1353-1357
Pentavalent Vaccine and Adverse Events Following Immunization—Untangling the Misinterpretations
In April 2008, the National Technical Group on Immunization (NTAGI) Sub-committee on H. influenza type b (Hib) vaccine recommended that Hib containing pentavalent vaccine should be introduced in the country. Subsequently liquid pentavalent vaccine (LPV) was launched in the Kerala and Tamil Nadu on a pilot basis in December 2011. The introduction of LPV in these two states was followed by reported deaths in infants who had received LPV. An exhaustive summary of media reports and previous literature has since been made available at various fora which have been supplemented with estimations of the damage the LPV may cause. It has thus been concluded that the LPV is bound to cause more number of infant deaths than it will save from Hib meningitis and pneumonia. The current paper aims to clear some of the misinterpretations and miscalculations so that lives of 72,000 infants can be saved.
- Open Access
- 1 January 2014
- Published by Medknow in Indian Journal of Community Medicine
- Vol. 39 (4) , 191-3
Zinc: An effective but neglected child survival intervention
Indian Journal of Community Medicine, the official organ of the Indian Association of Preventive and Social Medicine (IAPSM), India
- 1 January 2014
- Published by Medknow in Indian Journal of Community Medicine
- Vol. 39 (4) , 191-3
Open AccessZinc: An effective but neglected child survival intervention
Indian Journal of Community Medicine, the official organ of the Indian Association of Preventive and Social Medicine (IAPSM), India
- 1 July 2013
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 132 (1) , e46-e52
Short-Course Prophylactic Zinc Supplementation for Diarrhea Morbidity in Infants of 6 to 11 Months
BACKGROUND: Zinc supplementation during diarrhea substantially reduces the incidence and severity of diarrhea. However, the effect of short-course zinc prophylaxis has been observed only in children >12 months of age. Because the incidence of diarrhea is comparatively high in children aged 6 to 11 months, we assessed the prophylactic effect of zinc on incidence and duration of diarrhea in this age group. METHODS: In this randomized, double-blind, placebo-controlled trial, we enrolled infants aged 6 to 11 months from an urban resettlement colony in Delhi, India, between January 1, 2011, and January 15, 2012. We randomly assigned 272 infants to receive either 20 mg of zinc or a placebo suspension orally every day for 2 weeks. The primary outcome was the incidence of diarrhea per child-year. All analyses were done by intention-to-treat. RESULTS: A total of 134 infants in the zinc and 124 in the placebo groups were assessed for the incidence of diarrhea. There was a 39% reduction (crude incident rate ratio [IRR] 0.61, 95% confidence interval [CI] 0.53–0.71) in episodes of diarrhea, 39% (adjusted IRR 0.61, 95% CI 0.54–0.69) in the total number of days that a child suffered from diarrhea, and reduction of 36% in duration per episode of diarrhea (IRR 0.64, 95% CI 0.56–0.74) during the 5 months of follow-up. CONCLUSIONS: Short-course prophylactic zinc supplementation for 2 weeks may reduce diarrhea morbidity in infants of 6 to 11 months for up to 5 months, in populations with high prevalence of wasting and stunting.
- 1 July 2013
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 132 (1) , e46-e52
Short-Course Prophylactic Zinc Supplementation for Diarrhea Morbidity in Infants of 6 to 11 Months
BACKGROUND: Zinc supplementation during diarrhea substantially reduces the incidence and severity of diarrhea. However, the effect of short-course zinc prophylaxis has been observed only in children >12 months of age. Because the incidence of diarrhea is comparatively high in children aged 6 to 11 months, we assessed the prophylactic effect of zinc on incidence and duration of diarrhea in this age group. METHODS: In this randomized, double-blind, placebo-controlled trial, we enrolled infants aged 6 to 11 months from an urban resettlement colony in Delhi, India, between January 1, 2011, and January 15, 2012. We randomly assigned 272 infants to receive either 20 mg of zinc or a placebo suspension orally every day for 2 weeks. The primary outcome was the incidence of diarrhea per child-year. All analyses were done by intention-to-treat. RESULTS: A total of 134 infants in the zinc and 124 in the placebo groups were assessed for the incidence of diarrhea. There was a 39% reduction (crude incident rate ratio [IRR] 0.61, 95% confidence interval [CI] 0.53–0.71) in episodes of diarrhea, 39% (adjusted IRR 0.61, 95% CI 0.54–0.69) in the total number of days that a child suffered from diarrhea, and reduction of 36% in duration per episode of diarrhea (IRR 0.64, 95% CI 0.56–0.74) during the 5 months of follow-up. CONCLUSIONS: Short-course prophylactic zinc supplementation for 2 weeks may reduce diarrhea morbidity in infants of 6 to 11 months for up to 5 months, in populations with high prevalence of wasting and stunting.
- Open Access
- 1 January 2013
- Published by Medknow in Indian Journal of Community Medicine
- Vol. 38 (4) , 189-91
Conjugate pneumococcal vaccines: Need and choice in India
Indian Journal of Community Medicine, the official organ of the Indian Association of Preventive and Social Medicine (IAPSM), India
- 1 January 2013
- Published by Medknow in Indian Journal of Community Medicine
- Vol. 38 (4) , 189-91
Open AccessConjugate pneumococcal vaccines: Need and choice in India
Indian Journal of Community Medicine, the official organ of the Indian Association of Preventive and Social Medicine (IAPSM), India
- Open Access
- 1 January 2012
- Published by Medknow in Indian Journal of Public Health
- Vol. 56 (1) , 17-21
Burden of rotavirus in India - Is rotavirus vaccine an answer to it?
Rotavirus is currently by far the most common cause of severe diarrhea in infants and young children worldwide and of diarrheal deaths in developing countries. Worldwide Rotavirus is responsible for 611,000 childhood deaths out of which more than 80% occur in low-income countries. The resistance of rotavirus to commonly used disinfectants and ineffectiveness of oral rehydration therapy due to severe vomiting indicates that if an effective vaccine is the preferred option. WHO has recommended inclusion of rotavirus vaccine in the National Schedules where under 5 mortality due to diarrheal diseases is ≥ 10%. Currently two vaccines are available against rotavirus. Rotarix (GlaxoSmithKline) is a monovalent vaccine recommended to be orally administered in two doses at 6-12 weeks. Rota Teq (Merck) is a pentavalent vaccine recommended to be orally administered in three doses starting at 6-12 weeks of age. Serodiversity of rotavirus in India and its regional variation favor either a monovalent vaccine that can induce heterotypic immunity or a polyvalent vaccine incorporating majority of serotypes prevalent in the country. However, the efficacy of available rotavirus vaccines is less in low-income countries. Both the candidate vaccines when coadministered with OPV, immune response to first dose of these vaccines is reduced. However, immune responses to subsequent rotavirus vaccine doses are not affected. In view of this, WHO recommends three doses of either vaccine to be given to children in developing countries to produce the optimum response. Indigenous vaccine, 116E (Bharat Biotech) based on human rotavirus of serotype G9P [11] is still under Phase 2 trials. Another multivalent vaccine is being developed by Shantha Biotechnics in India. The cost effectiveness of the three dose schedule of the available and the rsults of the field trials of the indigenous vaccines should be assessed before inclusion of rotavirus vaccine in the National Immunization Schedule.
- 1 January 2012
- Published by Medknow in Indian Journal of Public Health
- Vol. 56 (1) , 17-21
Open AccessBurden of rotavirus in India - Is rotavirus vaccine an answer to it?
Rotavirus is currently by far the most common cause of severe diarrhea in infants and young children worldwide and of diarrheal deaths in developing countries. Worldwide Rotavirus is responsible for 611,000 childhood deaths out of which more than 80% occur in low-income countries. The resistance of rotavirus to commonly used disinfectants and ineffectiveness of oral rehydration therapy due to severe vomiting indicates that if an effective vaccine is the preferred option. WHO has recommended inclusion of rotavirus vaccine in the National Schedules where under 5 mortality due to diarrheal diseases is ≥ 10%. Currently two vaccines are available against rotavirus. Rotarix (GlaxoSmithKline) is a monovalent vaccine recommended to be orally administered in two doses at 6-12 weeks. Rota Teq (Merck) is a pentavalent vaccine recommended to be orally administered in three doses starting at 6-12 weeks of age. Serodiversity of rotavirus in India and its regional variation favor either a monovalent vaccine that can induce heterotypic immunity or a polyvalent vaccine incorporating majority of serotypes prevalent in the country. However, the efficacy of available rotavirus vaccines is less in low-income countries. Both the candidate vaccines when coadministered with OPV, immune response to first dose of these vaccines is reduced. However, immune responses to subsequent rotavirus vaccine doses are not affected. In view of this, WHO recommends three doses of either vaccine to be given to children in developing countries to produce the optimum response. Indigenous vaccine, 116E (Bharat Biotech) based on human rotavirus of serotype G9P [11] is still under Phase 2 trials. Another multivalent vaccine is being developed by Shantha Biotechnics in India. The cost effectiveness of the three dose schedule of the available and the rsults of the field trials of the indigenous vaccines should be assessed before inclusion of rotavirus vaccine in the National Immunization Schedule.